T

Texas Centers for Infectious Disease Associates | Fort Worth, TX

Research site

(Unclaimed)

Location

1025 College Avenue, Fort Worth, Texas, United States of America

Site insights

Top conditions

Top treatments

Lenacapavir

Bictegravir

Darunavir

DRV

COBI

ABBV-382

Tenofovir Alafenamide

FTC

Ritonavir

Cobicistat

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 9 total trials

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling

Human Immuno-deficiency Virus (HIV) Disease

Drug: Budigalimab

Drug: ABBV-382

Locations recently updated

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Enrolling

HIV-1 Infection

Drug: BIC/FTC/TAF

Drug: Placebo to DOR/ISL

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Enrolling

HIV-1-infection

Drug: Stable Baseline Regimen

Drug: Bictegravir

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy (ARTISTRY-2)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose c...

Enrolling

HIV-1-infection

Drug: B/F/TAF

Drug: Placebo to match B/F/TAF